Register below for the KromaTiD Webinar | Combining Synthetic and Evolutionary Biology Reveals DNA Therapy to Combat Cancer Chemoresistance Drug resistance is still an ongoing [...]
CAR T cell therapies have achieved substantial improvements in the prognoses of patients fighting advanced hematological malignancies, demonstrating robust efficacy in inducing durable remissions. While [...]
Solid tumors, with their intricate immune microenvironment, pose a formidable challenge to immunotherapy. Within this complex landscape, mast cells (MCs) and dendritic cells (DCs) emerge [...]
While immune checkpoint blockade therapies targeting T cells have shown promise, limitations arise in cases of tumor escape mechanisms, including HLA-I downregulation. Loss of HLA-I [...]
Cancer immunotherapy has witnessed remarkable advances in recent years, with much of the focus being on CAR-T cells. However, a great deal of research has [...]
Chimeric Antigen Receptor (CAR) T cells are the protagonist in the evolving story of adoptive immunotherapy research. The villain in the story is almost always [...]
Sickle cell disease (SCD) is a hereditary blood disorder caused by malformed β-globin protein in red blood cells. It has long been a target for [...]
For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene [...]
T cells, a frontline element in our bodies’ defense against pathogenic invaders, rely on the T cell receptor (TCR) to recognize enemies. This cell surface [...]
KromaTiD and SeQure Dx enter partnership agreement to offer comprehensive, IND-enabling gene editing services supporting cell and gene therapy research Longmont, CO. and Waltham, [...]
